9 September 2023 in Journal of Pediatric Surgery
4 March 2022 in American Journal of Obstetrics and Gynecology
CTChristina Paidas Teefey
+2
18 March 2024 in Prenatal Diagnosis
Background: Enlarged cavum septum pellucidum (CSP) and hypoplastic thymus are proposed extra-cardiac fetal markers for 22q11.2 deletion syndrome. We sought to determine if they were part of the fetal phenotype of our cohort of fetuses with 22q11.2 deletion syndrome. Methods: Case-control study of fetuses evaluated from 2016 to 2022. The study group included fetuses with laboratory confirmation of 22q11.2 deletion syndrome. The control group included pregnancies with conotruncal cardiac anomalies with normal microarray as well as structurally normal fetuses with normal microarray. The CSP and thymus were routinely measured during anatomical ultrasound in all patients at their initial visit at 27.1 +/- 4.7 weeks. The CSP and thymus measurements were classified as abnormal if they were >95% or <5% for gestational age, respectively. The groups were compared using analysis of variance or Kruskal-Wallis for continuous variables and Fisher's exact test for categorical variables. Logistic regression was performed, and a Receiver Operating Characteristic (ROC) curve was constructed. Results: We identified 47 fetuses with 22q11.2 deletion syndrome and compared them to 47 fetuses with conotruncal anomalies and normal microarray and 47 structurally normal fetuses with normal microarray. 51% (24/47) of fetuses with 22q11.2 deletion syndrome had an enlarged CSP compared to 6% (3/47) of fetuses with a conotruncal anomaly and normal microarray and none of the structurally normal fetuses (p < 0.001). Of the fetuses with 22q11.2 deletion syndrome, 83% (39/47) had a hypoplastic or absent thymus compared to 9% (4/47) of the fetuses with a conotruncal anomaly and normal microarray and none of the structurally normal fetuses (p < 0.001). 87% (41/47) of the fetuses with 22q11.2 deletion syndrome had conotruncal cardiac anomalies. Logistic regression revealed that both enlarged CSP and hypoplastic/absent thymus were associated with 22q11.2 deletion syndrome. The area under the ROC curve for the two markers was 0.94. Conclusion: An enlarged CSP and hypoplastic/absent thymus appear to be part of the fetal phenotype of 22q11.2 deletion syndrome. These markers are associated with conotruncal anomalies in the setting of 22q11.2 deletion syndrome but not in normal controls or fetuses with conotruncal defects and normal microarrays.
1 April 2025 in Prenatal Diagnosis
Objective: To define the ultrasound observed/expected lung‐to‐head ratio (O/E LHR) and magnetic resonance imaging (MRI) observed/expected total lung volume (O/E TLV) cut‐offs associated with survival and lack of extracorporeal membrane oxygenation (ECMO) utilization to determine the most severe cohort that may benefit from fetal intervention.Methods: Retrospective review of patients with a prenatal diagnosis of isolated left or right congenital diaphragmatic hernia (L CDH, R CDH) seen and delivered at our level III fetal center from January 2013–July 2023. Data were extracted from our clinical outcome database. Characteristics of survivors and non‐survivors were compared for both the L CDH and R CDH groups. For both O/E LHR and O/E TLV, the Youden criteria were then used to determine a good sensitivity and specificity for predicting survival and ECMO utilization for L and R CDH, respectively, in Receiver Operator Characteristic (ROC) curve analysis.Results: 340 patients were included in the study, including 283 (83.2%) with L CDH and 57 (16.8%) with R CDH. The median [interquartile range, IQR] O/E LHR for L and R CDH was 37.9 [28.7–47.3] and 49.0 [40.0–64.5], respectively. The median O/E TLV for L and R CDH was 36.0 [28.0–48.0] and 25.3 [23.6–29.8], respectively. For survival, an O/E LHR of 28.1% and O/E TLV of 34.0% and an O/E LHR of 46.8% and O/E TLV of 17.6% were the best cut‐offs for L and R CDH, respectively. For ECMO utilization, an O/E LHR of 32.8% and O/E TLV of 35.3% and an O/E LHR of 47.0% and O/E TLV of 22.0% were the best cut‐offs for L and R CDH, respectively.Conclusion: We report the best ultrasound O/E LHR and MRI TLV cut‐offs associated with survival and lack of ECMO utilization in our cohort.
1 January 2025 in Prenatal Diagnosis
22 June 2025 in Journal of Child Neurology
Agenesis of the corpus callosum (ACC) has a wide spectrum of anatomic manifestations associated with incompletely understood clinical variability. In this retrospective cohort study, 161 children with ACC were classified into complete ACC and partial ACC. Partial and complete ACC diagnoses were confirmed by postnatal magnetic resonance imaging (MRI) and further classified as isolated or complex (associated with other brain abnormalities or genetic diagnoses). Clinical characteristics, clinical outcomes, and co-occurring genetic variations were collected by chart review. Median age at last neurologic evaluation for the complete and partial ACC cohorts were 2.8 years and 2.3 years, respectively; thus, an average of 2-3 years of follow-up data were analyzed per patient. Results showed that children with complete and partial ACC had similar birth characteristics. Children with complete ACC were more frequently diagnosed prenatally; additionally, complete ACC patients had lower rates of cerebral palsy. When comparing complex complete ACC and complex partial ACC to isolated complete ACC and isolated partial ACC, respectively, the complex subcohorts had a higher level of motor delay, assistive device use, cerebral palsy, ventriculoperitoneal shunt placement, epilepsy, language delay, and cognitive delay than the isolated subcohorts. About 50% of children had genetic variants associated with neurodevelopmental disorders in this cohort. Additionally, >50% of our patients with motor and nonmotor developmental delays, as well as >60% of patients that required assistive devices and had cerebral palsy, were also found to have genetic anomalies. Although research describing ACC and its outcomes is expanding, there is still a need for large cohort studies with robust follow-up data to help further understand the disease.